Azenta (NASDAQ:AZTA) reported fiscal second-quarter 2026 results that management said fell short of expectations, citing ...

Second quarter performance came in below our expectations and reflect continued divergence across our segments with softness in Multiomics driven by lower volumes in North America and a decline in ...

Needham analyst David Saxon reiterated a Buy rating on Azenta today and set a price target of $33.00. Saxon covers the Healthcare sector, focusing on stocks such as DENTSPLY SIRONA, Staar Surgical, ...

TD Cowen analyst Brendan Smith maintained a Hold rating on Azenta today and set a price target of $20.00. Smith covers the Healthcare sector, focusing on stocks such as Repligen, Halozyme, and West ...

FY'26 total reported revenue from continuing operations to range between approximately $603 to $621 millionFY'26 organic ...

Azenta, Inc. (NASDAQ:AZTA) is one of the 10 Best Medical Stocks to Buy Under $30. On April 6, Evercore ISI reduced its price ...

"Second quarter results reflect a combination of solid progress on the Services side of the business offset by timing-related issues impacting performance in Products, most notably in B Medical. We ...

Azenta (NASDAQ:AZTA) is preparing to release its quarterly earnings on Tuesday, 2024-11-12. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Business: Azenta is a life sciences company that operates through two segments. First, there's the life sciences products division, which offers automated cold sample management systems for compound ...

"Our third quarter results reflect positive momentum in both organic revenue growth and profitability. Our go-to-market initiatives continue to gain traction while our cost reduction efforts are ...

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big ...